DUBLIN, June 4, 2015 /PRNewswire/ —
Research and Markets (
http://www.researchandmarkets.com/research/dxrpmh/noninvasive) has announced the
addition of the”Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony,
informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, verifi, VisibiliT and Others) –
Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 – 2022″
[http://www.researchandmarkets.com/research/dxrpmh/noninvasive ] report to their offering.
(Logo:
http://photos.prnewswire.com/prnh/20130307/600769 )
The exponential growth of the NIPT market is supported by factors such as high
incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT, and
shifting trend toward child bearing at advanced maternal age (35 years or older). Maternal
age is closely associated with the risk of developing a fetus with chromosomal
abnormalities; hence, rising maternal age is likely to contribute to the increasing
incidence of babies born with chromosomal aneuploidies.
According to Down Syndrome Education (DSE), the incidence rate for Down syndrome is
one in every 830 child births (around 4,700 annually) in the U.S., while the incidence
rate is one in every 920 babies born (around 9,000 annually) in Europe, indicating a large
potential consumer base for NIPT. Conventional invasive prenatal genetic tests such as
amniocentesis and chorionic villus sampling (CVS) are associated with the risk of
miscarriage; hence, these are being replaced with new non-invasive prenatal tests. These
new NIPTs are based on the analysis of cell-free DNA floating in the maternal plasma and
pose no risk of miscarriage.
North America held the largest share of the global NIPT market in terms of revenue as
well as volume in 2013, accounting for 58.8% and 51.0%, respectively, of the market. Major
players domiciled in the U.S. and relatively high awareness levels about NIPT in North
America are the key factors attributed to the region’s leadership position. In Europe,
market growth largely depends upon increasing penetration of these U.S.-based test
developers and increase in acceptance of these tests.
Japan, Australia, China, and India represent high growth potential markets in
Asia-Pacific. Large population of women preferring late pregnancy is likely to act as a
major driver of the NIPT market in the region. The NIPT market in China is dominated by
two local players: BGI Diagnostics and Berry Genomics. In addition, the recent CFDA
approval for BambniTest would propel the growth of the market in this region.
Sequenom, Inc., Illumina, Inc. (Verinata Health, Inc.), Ariosa Diagnostics, Natera,
Inc., BGI Health, LifeCodexx AG, LabCorp, and Berry Genomics are the key players competing
in the non-invasive prenatal testing market.
These players operate by marketing their proprietary non-invasive prenatal tests by
forming alliances with hospitals, clinical laboratories, and physician offices.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Global Non-Invasive Prenatal Testing Market Overview
Chapter 4 Global Non-Invasive Prenatal Testing Market Revenue (USD Million) and Volume
(Number of Tests Performed), by Test
Chapter 5 Global Non-Invasive Prenatal Testing Market Revenue (USD Million) and Volume
(Number of Tests Performed), by Geography
Chapter 6 Recommendations
Chapter 7 Company Profiles
- Ariosa Diagnostics, Inc.
- BGI Diagnostics
- Berry Genomics Co., Ltd.
- Illumina, Inc.
- Laboratory Corporation of America Holdings (LabCorp)
- LifeCodexx AG
- Natera, Inc.
- Sequenom, Inc.
For more information visit
http://www.researchandmarkets.com/research/dxrpmh/noninvasive
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
Photo:
http://photos.prnewswire.com/prnh/20130307/600769
SOURCE Research and Markets
Comments